Left Ventricular Hypertrophy Reduction With Statins in Hypertensives Patients.
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 发起方
- 入组人数
- 12
- 主要终点
- Left Ventricular Hypertrophy Reduction With Statins in Hypertensive Patients
研究概览
简要总结
Evaluate pleiotropic effects of simvastatin in hypertensive patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Females Or Males Over 18 Years Old
- •Patients With Systemic Arterial Hypertension Grade I And II According With The European Society Of Cardiology
- •Left Ventricular hypertrophy Demonstrated By Echocardiography
- •Mild To Moderated hypercholesterolemia
- •Willing To Participate And Sign The Informed Consent Form (ICF)
排除标准
- •Type 1 Or 2 Diabetes Mellitus
- •Familiar hypercholesterolemia
- •Low Density Lipoprotein-Cholesterol (LDL-C) > 190 mg/dl
- •History Of Myocardial Infarction Or Stable Chronic Angina
- •Triglycerides >250 mg/dl
研究组 & 干预措施
Valsartan 80 mg + Paravastin 40 mg
Participants who were administered Valsartan 80 mg plus paravastin 40 mg by mouth daily for one year. (Group A)
干预措施: valsartan (Drug)
Valsartan 80 mg + Paravastin 40 mg
Participants who were administered Valsartan 80 mg plus paravastin 40 mg by mouth daily for one year. (Group A)
干预措施: pravastatin (Drug)
Valsartan 80 mg + Simvastatin 40 mg
Participants who were administered Valsartan 80 mg plus simvastatin 40 mg by mouth daily for one year. (Group B)
干预措施: valsartan (Drug)
Valsartan 80 mg + Simvastatin 40 mg
Participants who were administered Valsartan 80 mg plus simvastatin 40 mg by mouth daily for one year. (Group B)
干预措施: simvastatin (Drug)
Valsartan 80 mg + Simvastatin 40 mg / Ezetimibe 10 mg
Participants who were administered Valsartan 80 mg plus simvastatin 40 mg / ezetimibe 10 mg by mouth daily for one year. (Group C)
干预措施: valsartan (Drug)
Valsartan 80 mg + Simvastatin 40 mg / Ezetimibe 10 mg
Participants who were administered Valsartan 80 mg plus simvastatin 40 mg / ezetimibe 10 mg by mouth daily for one year. (Group C)
干预措施: ezetimibe (+) simvastatin (Drug)
Valsartan 80 mg
Participants who were administered Valsartan 80 mg by mouth daily for one year. (Group D)
干预措施: valsartan (Drug)
结局指标
主要结局
Left Ventricular Hypertrophy Reduction With Statins in Hypertensive Patients
时间窗: 6 Month(s)
Left ventricular hypertrophy reduction was to be measured by echocardiography.
次要结局
未报告次要终点